The Value of Addressing Patient Preferences

Value in Health

Volumn 20, Issue 2, 2017, Pages 283-285

  Allen, Jeff D ^a   Stewart, Mark D ^a   Roberts, Samantha A ^a   Sigal, Ellen V ^a  

^a Friends of Cancer Research   (United States)

Author keywords

assessment; breakthrough therapies; cancer; value framework

Indexed keywords

ARTICLE; CANCER SURVIVAL; CLINICAL RESEARCH; HEALTH CARE SYSTEM; HUMAN; MALIGNANT NEOPLASM; OVERALL SURVIVAL; PATIENT PREFERENCE; PATIENT-REPORTED OUTCOME; PRIORITY JOURNAL; STUDY DESIGN; DRUG DEVELOPMENT; NEOPLASMS; PURCHASING;

ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC AGENTS; DRUG DISCOVERY; HUMANS; NEOPLASMS; PATIENT PREFERENCE; VALUE-BASED PURCHASING;

EID: 85013634131     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2016.11.029     Document Type: Article

References (14)

1. [1] Schnipper, L.W., Davidson, N.E., Wollins, D.S., et al. Updating the American Society of Clinical Oncology Value Framework: revisions and reflections in response to comments received. J Clin Oncol 34 (2016), 2925–2934.
2. [2] Chernyl, N.I., Sullivan, R., Dafni, U., et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies. Ann Oncol 26 (2015), 1547–1573.
3. [3] Institute for Clinical and Economic Review. Evaluating the value of new drugs and devices. Available from: https://icer-review.org/methodology/icers-methods/icer-value-assessment-framework/ [Accessed September 30, 2016].
4. [4] Memorial Sloan Kettering Cancer Center. DrugAbacus website. Available from: http://drugabacus.org [Accessed September 30, 2016].
5. [5] National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) with NCCN Evidence Blocks. Available from: http://www.nccn.org/evidenceblocks/ [Accessed September 30, 2016].
6. [6] Chandra, A., Shafrin, J., Dhawan, R., Utility of cancer value frameworks for patients, payers, and physicians. JAMA 315 (2016), 2069–2070.
7. [7] Neumann, P.J., Cohen, J.T., Measuring the value of prescription drugs. N Engl J Med 373 (2015), 2595–2597.
8. [8] Sridhara, R., Johnson, J.R., Justice, R., et al. Review of oncology and hematology drug product approvals at the US Food and Drug Administration between July 2005 and December 2007. J Natl Cancer Inst 102 (2010), 230–243.
9. [9] Korn, E.L., Freidlin, B., Abrams, J.S., Overall survival as the outcome for randomized clinical trials with effective subsequent therapies. J Clin Oncol 29 (2011), 2439–2442.
10. [10] Jönsson, L., Sandin, R., Ekman, M., et al. Analyzing overall survival in randomized controlled trials with crossover and implications for economic evaluation. Value Health 17 (2014), 707–713.
11. [11] Tevaarwerk, A.J., Lee, J.W., Terhaar, A., et al. Working after a metastatic cancer diagnosis: factors affecting employment in the metastatic setting from ECOG-ACRIN׳s symptom outcomes and practice patterns study. Cancer 122 (2016), 438–446.
12. [12] Lu, Y., Penrod, J.R., Sood, N., et al. Dynamic cost-effectiveness of oncology drugs. Am J Manag Care 18:Suppl 11 (2012), S249–S256.
13. [13] Hill, T., Conducting phase IV clinical studies: a moral imperative?. Ecancermedicalscience, 6, 2012, 276.
14. [14] Institute of Medicine. Clinical Data as the Basic Staple of Health Learning: Creating and Protecting a Public Good: Workshop Summary. 2010, The National Academies Press, Washington, DC.